Table 3.
Genotype frequency and gliclazide CL/F in 21 subjects in gliclazide only phase
| CYP2C9 genotype | Samples (n) | Frequency (%) | Gliclazide CL/F (ml h−1 kg−1) |
|---|---|---|---|
| *1/*1 | 11 | 52.4 | 24.0 (19.0–28.9) |
| *1/*2 or | 6 | 28.6 | 18.5 (15.2–21.7) |
| *2/*2 | 1 | 4.8 | |
| *1/*3 | 3 | 14.3 | 25.4 (20.4–30.5) |
Abbreviation: CL/F, apparent clearance.
Data shown was not to represent population frequency; data are presented as median and range.